📇 Rhumatologue · PARIS CEDEX 12 · (75) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Praticien-chercheur
5 articles scientifiques publiés — formation continue solide
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
4 publications sur 5 ans
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Influence scientifique
5
5 articles ont été cités au moins 5fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
65
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
8
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
3
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Assistance Publique – Hôpitaux de Paris
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM study
2025ArticleEuropean Journal of Neurology
Highly effective therapies as first-line treatments for pediatric onset multiple sclerosis in a French nationwide cohort
2023Congrès9th Joint ECTRIMS-ACTRIMS meeting
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference
2023ArticleNeurology
Long-term prognosis of fatty-acid oxidation disorders in adults: Optimism despite the limited effective therapies available
2023ArticleEuropean Journal of Neurology
Improving the decision to switch from first to second-line therapy in MS: a dynamic scoring system
2021Congrès37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2021)
Untreated patients with multiple sclerosis: A study of French expert centers
2021ArticleEuropean Journal of Neurology
Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders
2020ArticleEuropean Journal of Neurology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CHNO DES QUINZE VINGTS PARIS
28 R DE CHARENTON, 75571 PARIS CEDEX 12
CDS PIERRE ROUQUES SITE MARX
43 AV KARL MARX, 94800 VILLEJUIF
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
European journal of neurology · 2021
AbstractBackgroundOutcomes of coronavirus disease 2019 (COVID‐19) in patients with neuromyelitis optica spectrum disorders (NMOSD) or myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), often treated with immunosuppressive therapies, are still unknown.MethodsWe conducted a multicenter, retrospective, observational cohort study among all French expert centers for neuromyelitis optica and related disorders. Patients with NMOSD or MOGAD included in the study received a confirmed or highly suspected diagnosis of COVID‐19 between 1 March 2020 and 30 June 2020. Main outcome was COVID‐19 severity score assessed on a seven‐point ordinal scale ranging from 1 (not hospitalized with no limitations on activities) to 7 (death).ResultsFifteen cases (mean [SD] age: 39.3 [14.3] years, 11 female) were included. Five patients (33.3%) were hospitalized, all receiving rituximab. A 24‐year‐old patient with positive aquaporine‐4 antibody, with obesity as comorbidity, needed mechanical ventilation. Outpatients were receiving anti‐CD20 (5), mycophenolate mofetil (3) or azathioprine (3). They were younger (mean [SD] age: 37.0 [13.4] years), with a longer disease duration (mean [SD]: 8.3 [6.3] years) and had a lower expanded disability severity score (EDSS) score (median [range] EDSS: 2.5 [0–4]) relative to patients requiring hospitalization (mean [SD] age: 44.0 [16.4] years, mean [SD] disease duration: 5.8 [5.5] years, median [range] EDSS: 4 [0–6.5]).ConclusionsCOVID‐19 outcome was overall favorable in this cohort. Larger international studies are needed to identify risk factors of severe COVID‐19; however, we recommend personal protective measures to reduce risk of SARS‐CoV‐2 infection in this immunocompromised population.
European journal of neurology · 2021
AbstractBackground and purposeDisease‐modifying therapies (DMTs) have an impact on relapses and disease progression. Nonetheless, many patients with multiple sclerosis (MS) remain untreated. The objectives of the present study were to determine the proportion of untreated patients with MS followed in expert centers in France and to determine the predictive factors of nontreatment.MethodsWe conducted a retrospective cohort study. Data were extracted from the 38 centers participating in the European Database for Multiple Sclerosis (EDMUS) on December 15, 2018, and patients with MS seen at least once during the study period (from June 15, 2016 to June 14, 2017) were included.ResultsOf the 21,189 patients with MS (age 47.1 ± 13.1 years; Expanded Disability Status Scale (EDSS) score 3.4 ± 2.4), 6,631 (31.3%; 95% confidence interval [CI] 30.7–31.9) were not receiving any DMT. Although patients with a relapsing‐remitting course (n = 11,693) were the most likely to receive DMT, 14.8% (95% CI 14.2–15.4) were still untreated (6.8% never treated). After multivariate analysis among patients with relapsing‐remitting MS, the main factors explaining never having been treated were: not having ≥9 lesions on brain magnetic resonance imaging (odds ratio [OR] 0.52 [95% CI 0.44–0.61]) and lower EDSS score (OR 0.78 [95% CI 0.74–0.82]). Most patients with progressive MS (50.4% for secondary and 64.2% for primary progressive MS) did not receive any DMT during the study period, while 11.6% of patients with secondary and 34.0% of patients with primary progressive MS had never received any DMT.ConclusionA significant proportion of patients with MS did not receive any DMT, even though such treatments are reimbursed by the healthcare system for French patients. This result highlights the unmet need for current DMTs for a large subgroup of patients with MS.
European journal of neurology · 2024
AbstractIntroductionFatty‐acid oxidation disorders (FAODs) are recessive genetic diseases.Materials and methodsWe report here clinical and paraclinical data from a retrospective study of 44 adults with muscular FAODs from six French reference centers for neuromuscular or metabolic diseases.ResultsThe study cohort consisted of 44 adult patients: 14 with carnitine palmitoyl transferase 2 deficiency (32%), nine with multiple acyl‐CoA deficiency (20%), 13 with very long‐chain acyl‐CoA dehydrogenase deficiency (30%), three with long‐chain 3‐hydroxyacyl‐CoA dehydrogenase deficiency (7%), and five with short‐chain acyl‐CoA dehydrogenase deficiency (11%). Disease onset occurred during childhood in the majority of patients (59%), with a mean age at onset of 15 years (range = 0.5–35) and a mean of 12.6 years (range = 0–58) from disease onset to diagnosis. The principal symptoms were acute muscle manifestations (rhabdomyolysis, exercise intolerance, myalgia), sometimes associated with permanent muscle weakness. Episodes of rhabdomyolysis were frequent (84%), with a mean creatinine kinase level of 68,958 U/L (range = 660–300,000). General metabolic complications were observed in 58% of patients, respiratory manifestations in 18% of cases, and cardiological manifestations in 9% of cases. Fasting acylcarnitine profile was used to orient genetic explorations in 65% of cases. After a mean follow‐up of 10 years, 33% of patients were asymptomatic and 56% continued to display symptoms after exercise. The frequency of rhabdomyolysis decreased after diagnosis in 64% of cases.ConclusionA standardized register would complete this cohort description of muscular forms of FAODs with exhaustive data, making it possible to assess the efficacy of therapeutic protocols in real‐life conditions and during the long‐term follow‐up of patients.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
European journal of neurology · 2024 · Journal Article
Konecki C, Francou B, Chappell K, Augey L, et al.
European journal of neurology · 2024 · Journal Article
Rouyer A, Tard C, Dessein AF, Spinazzi M, et al.
Multiple sclerosis (Houndmills, Basingstoke, England) · 2023 · Journal Article
Sabathé C, Casey R, Vukusic S, Leray E, et al.
European journal of neurology · 2021 · Journal Article
Louapre C, Maillart E, Papeix C, Zeidan S, et al.
European journal of neurology · 2021 · Journal Article
Moisset X, Fouchard AA, Pereira B, Taithe F, et al.
Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system
Background:In relapsing-remitting multiple sclerosis (RRMS), early identification of suboptimal responders can prevent disability progression.Objective:We aimed to develop and validate a dynamic score to guide the early
Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system
Background:In relapsing-remitting multiple sclerosis (RRMS), early identification of suboptimal responders can prevent disability progression.Objective:We aimed to develop and validate a dynamic score to guide the early
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).